Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.57

-0.8%

Nov 3 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (1336)	6/1/2002 1:33:58 PM
From: Arthur Radley	Read Replies (1) of 1475

OT: Anyone know anything about this company? MicroIslet(MIIS) technologies represent state-of-the-art methods for the production of vastly improved microencapsulated islet cells in the four important areas: -A long-standing problem in the art of xenotransplantation is the rapid and profound loss of functionality of islet cells once harvested from the donor animal. MicroIslet's culturing techniques are optimized to preserve "freshly harvested" functionality profiles. -Freezing islet cells is a process that typically leads to widespread functional compromise. MicroIslet's technologies allow for freezing and thawing of islet cells without cellular death or significant losses in glucose responsiveness. This important advance makes the business of xenotransplantation of islet cells possible. Our technology can enable isolation of vast quantities of islet cells from donors and the safe cryopreservation and shipment of the cells anywhere in the world for later microencapsulation and transplantation. Our technology can eliminate the need for close proximity between the donor islet cell sources and the targeted patients. -Another limiting step in the prior art is that islet cells undergo significant loss of functionality because of the microencapsulation process. The treatment of microencapsulated islet cells in the companies' proprietary culturing mediums, prior to transplantation, is believed to eliminate the typical post-microencapsulation loss of functionality. -The structural integrity of current microencapsulated islets rapidly deteriorates over time. MicroIslet has discovered that a final incubation of microencapsulated islet cells in certain agents results in a substantially more durable microencapsulate than has ever been produced before. This proprietary process does not appear to interfere with the functional responsiveness of the cells. dukenews.duke.edu

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next